5 Key Takeaways
-
1
Nanoscope Therapeutics's MCO-010 shows durable BCVA improvements in retinitis pigmentosa (RP) after 3 years of treatment.
-
2
The therapy targets bipolar cells, allowing vision restoration without the need for goggles, even in low ambient light.
-
3
In the RESTORE trial, 40% of patients receiving MCO-010 improved by 0.3 logMAR, equating to approximately 3 lines on the visual acuity chart.
-
4
Cumulative vision improvement was observed over 152 weeks, with better outcomes linked to higher baseline visual acuity and less retinal thinning.
-
5
The safety profile of MCO-010 was positive, with mild to moderate adverse events that resolved with topical therapy and no serious adverse events.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
